Medtronic EVP sells 4,189 shares in open market

Medtronic plc executive Harry Skip Kiil reported selling Ordinary Shares in two open-market transactions.

Rhea-AI Filing Summary

Medtronic plc executive Harry Skip Kiil reported selling Ordinary Shares in two open-market transactions. On June 8, 2026, he sold a total of 4,189 Medtronic Ordinary Shares in the open market at prices around $80.44–$80.45 per share. These are non-derivative transactions reported as direct ownership and represent routine insider sales rather than option exercises or gifts.

Insights

Insider trading analyst

Medtronic EVP sells 4,189 shares in routine open-market trades.

Executive Vice President and Cardiovascular President Harry Skip Kiil executed two open-market sales of Medtronic Ordinary Shares on June 8, 2026, totaling 4,189 shares at about $80.44–$80.45 per share. The transactions involve common equity, not options or other derivatives.

Form 4 data classify both transactions with code S as open-market or private sales, with direct ownership and no derivative positions reported in this filing. Given the modest size and absence of related exercises or restructuring, this looks like a routine liquidity event rather than a strategic change in exposure.

Insider Trade Summary

Net Seller: 4,189 shares

Net Sell 2 txns

Insider KIIL HARRY SKIP

Role EVP & President Cardiovascular

Sold 4,189 shs ($337K)

Type	Security	Shares	Price	Value
Sale	Ordinary Shares	3,961	$80.44	$319K
Sale	Ordinary Shares	228	$80.45	$18K

Holdings After Transaction: Ordinary Shares — 37,227 shares (Direct)

Key Figures

Total shares sold: 4,189 shares Sale tranche 1: 228 shares at $80.45 Sale tranche 2: 3,961 shares at $80.44 +2 more

5 metrics

Total shares sold 4,189 shares Aggregate non-derivative sales on June 8, 2026

Sale tranche 1 228 shares at $80.45 Non-derivative open-market sale on June 8, 2026

Sale tranche 2 3,961 shares at $80.44 Non-derivative open-market sale on June 8, 2026

Shares after tranche 1 37,227 shares Total shares following first reported sale

Shares after tranche 2 37,455 shares Total shares following second reported sale

Key Terms

Form 4, open-market sale, non-derivative, Ordinary Shares

4 terms

Form 4 regulatory

"According to a new Form 4 insider filing as routine equity sales"

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

open-market sale financial

"transaction_action is described as an open-market sale for each entry"

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

non-derivative financial

"These are non-derivative transactions reported as direct ownership"

Ordinary Shares financial

"He sold a total of 4,189 Medtronic Ordinary Shares in the open market"

Ordinary shares are a type of ownership stake in a company, giving shareholders a right to participate in the company’s profits and decision-making through voting. They are similar to owning a piece of a business, and their value can rise or fall based on the company's performance. Investors buy ordinary shares to potentially earn dividends and benefit from the company's growth over time.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Medtronic (MDT) report for Harry Skip Kiil?

Medtronic reported that executive Harry Skip Kiil sold Medtronic Ordinary Shares in two open-market transactions. These non-derivative sales occurred on June 8, 2026, and are disclosed on a Form 4 insider filing as routine equity sales by a senior executive.

How many Medtronic (MDT) shares did Harry Skip Kiil sell on June 8, 2026?

Harry Skip Kiil sold a total of 4,189 Medtronic Ordinary Shares on June 8, 2026. The Form 4 transactionSummary aggregates two separate open-market sale entries, reflecting a net-sell direction and total sellShares of 4,189 for that trading day.

At what prices were the Medtronic (MDT) shares sold by Harry Skip Kiil?

The reported Medtronic Ordinary Share sales were executed at approximately $80.44 and $80.45 per share. One transaction covered 228 shares at $80.45, and another covered 3,961 shares at $80.44, according to the detailed non-derivative transaction lines in the Form 4.

Were Harry Skip Kiil’s Medtronic (MDT) trades option exercises or regular share sales?

The trades were regular share sales of Medtronic Ordinary Shares, not option exercises. The Form 4 classifies both entries as non-derivative transactions with code S, described as sales in open market or private transactions, and shows no related derivative exercises in derivativeSummary.

Does the Medtronic (MDT) Form 4 show insider buying or selling activity overall?

The Form 4 shows net insider selling activity by Harry Skip Kiil. The transactionSummary reports sellCount of 2, sellShares of 4,189, and a netBuySellDirection of net-sell, with no recorded purchases, exercises, gifts, or tax-withholding entries in this filing.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/09/2026 - 04:16 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

KIIL HARRY SKIP

(Last) (First) (Middle)

710 MEDTRONIC PARKWAY

(Street)

MINNEAPOLIS MINNESOTA 55432

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Medtronic plc [ MDT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP & President Cardiovascular

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/08/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Ordinary Shares	06/08/2026		S		3,961	D	$80.44	37,455	D
Ordinary Shares	06/08/2026		S		228	D	$80.45	37,227	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

Remarks:

	/s/ Patricia Walesiewicz, attorney-in-fact	06/09/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)